[EN] GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS<br/>[FR] COMPOSÉS DE VANCOMYCINE À EXTRÉMITÉ C-TERMINALE MODIFIÉE PAR DE LA GUANIDINE, COMPOSITIONS ET PROCÉDÉS
申请人:SCRIPPS RESEARCH INST
公开号:WO2021216323A1
公开(公告)日:2021-10-28
A series of vancomycin C-terminus guanidine modifications are disclosed that improve antimicrobial activity, enhance the durability of antimicrobial action against selection or induction of resistance, and provide two synergistic mechanisms of action independent of D-Ala-D-Ala binding that cause inhibition of cell wall biosynthesis, while inducing bacterial cell permeability. A contemplated compound contains two combined peripheral modifications, a (4-chlorobiphenyl)methyl (CBP) and C-terminus guanidine modification, that provide new treatments against not only vancomycin-sensitive, but especially vancomycin- resistant bacteria. The data demonstrate that the synergistic behavior of the peripheral modifications requires the presence of both the CBP and guanidine modifications in a single molecule versus their combined use as an equimolar mixture of singly modified compounds. A prototypical member of the series, G3- CBP-vancomycin (15), exhibits no hemolytic activity, displays no mammalian cell growth inhibition, and possesses improved and especially attractive in vivo pharmacokinetic (PK) properties.
披露了一系列万古霉素C-末端胍基修饰,可改善抗微生物活性,增强抗微生物作用对抗选择或诱导耐药性的耐久性,并提供两种独立于D-Ala-D-Ala结合的协同作用机制,导致细胞壁生物合成的抑制,同时诱导细菌细胞渗透性。一个可考虑的化合物包含两个组合的外围修饰,即(4-氯联苯)甲基(CBP)和C-末端胍基修饰,可提供新的治疗方法,不仅针对万古霉素敏感的细菌,特别是针对万古霉素耐药菌。数据表明,外围修饰的协同行为需要在单个分子中同时存在CBP和胍基修饰,而不是将它们作为等摩尔混合物的单一修饰化合物的组合使用。该系列的典型成员G3-CBP-万古霉素(15)不表现出溶血活性,不抑制哺乳动物细胞生长,并具有改进的特别有吸引力的体内药物动力学(PK)特性。